Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations

Journal of General Virology

Volumn 92, Issue 1, 2011, Pages 128-140

  Cristillo, Anthony D ^a   Ferrari, Maria Grazia ^a   Hudacik, Lauren ^a   Lewis, Brad ^a   Galmin, Lindsey ^a   Bowen, Britany ^a   Thompson, DeVon ^a   Petrovsky, Nikolai ^b   Markham, Phillip ^a   Pal, Ranajit ^a  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b VAXINE PTY LTD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SECRETIONS; SERUM; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS; PRIMATES;

EID: 78651250984     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.023242-0     Document Type: Article

References (88)

1. Ahmed, R. K., Biberfeld, G. & Thorstensson, R. (2005). Innate immunity in experimental SIV infection and vaccination. Mol Immunol 42, 251-258.
2. Alving, C. R. & Rao, M. (2008). Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26, 3036-3045.
3. Asahi-Ozaki, Y., Yoshikawa, T., Iwakura, Y., Suzuki, Y., Tamura, S., Kurata, T. & Sata, T. (2004). Secretory IgA antibodies provide crossprotection against infection with different strains of influenza B virus. J Med Virol 74, 328-335.
4. Barnett, S. W., Srivastava, I. K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A. D., Ferrai, M. G., Weiss, D. E., Letvin, N. L. & other authors (2008). Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22, 339-348.
5. Barone, F., Patel, P., Sanderson, J. D. & Spencer, J. (2009). Gut-associated lymphoid tissue contains the molecular machinery to support T-cell-dependent and T-cell-independent class switch recombination. Mucosal Immunol 2, 495-503.
6. + CTLs in delay of AIDS viral dissemination from mucosa. Blood 107, 3258-3264.
7. Bertley, F. M., Kozlowski, P. A., Wang, S. W., Chappelle, J., Patel, J., Sonuyi, O., Mazzara, G., Montefiori, D., Carville, A. & other authors (2004). Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 172, 3745-3757.
8. Bradac, J. & Dieffenbach, C. W. (2009). HIV vaccine development: lessons from the past, informing the future. IDrugs 12, 435-439.
9. Bradney, C. P., Sempowski, G. D., Liao, H. X., Haynes, B. F. & Staats, H. F. (2002). Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 76, 517-524.
10. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200, 749-759.
11. Carroll, M. C. (1998). The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16, 545-568.
12. + regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol 81, 12748-12757.
13. Connell, T. D. (2007). Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 6, 821-834.
14. Cooper, P. D. (1995). Vaccine adjuvants based on gamma inulin. Pharm Biotechnol 6, 559-580.
15. Cooper, P. D., McComb, C. & Steele, E. J. (1991). The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 9, 408-415.
16. Couch, R. B. (2004). Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 350, 860-861.
17. Cristillo, A. D., Wang, S., Caskey, M. S., Unangst, T., Hocker, L., He, L., Hudacik, L., Whitney, S., Keen, T. & other authors (2006). Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346, 151-168.
18. Cristillo, A. D., Weiss, D., Hudacik, L., Restrepo, S., Galmin, L., Suschak, J., Draghia-Akli, R., Markham, P. & Pal, R. (2008a). Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 366, 29-35.
19. Cristillo, A. D., Galmin, L., Restrepo, S., Hudacik, L., Suschak, J., Lewis, B., Draghia-Akli, R., Aziz, N., Weiss, D. & other authors (2008b). HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat. Biochem Biophys Res Commun 370, 22-26.
20. Denton, P. W. & Garcia, J. V. (2009). Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 6, 13-19.
21. Devito, C., Broliden, K., Kaul, R., Svensson, L., Johansen, K., Kiama, P., Kimani, J., Lopalco, L., Piconi, S. & other authors (2000). Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165, 5170-5176.
22. Devito, C., Hinkula, J., Kaul, R., Kimani, J., Kiama, P., Lopalco, L., Barass, C., Piconi, S., Trabattoni, D. & other authors (2002). Crossclade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 30, 413-420.
23. Finerty, S., Stokes, C. R., Gruffydd-Jones, T. J., Hillman, T. J., Barr, F. J. & Harbour, D. A. (2001). Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20, 49-58.
24. Fujii, S., Shimizu, K., Hemmi, H., Fukui, M., Bonito, A. J., Chen, G., Franck, R. W., Tsuji, M. & Steinman, R. M. (2006). Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A 103, 11252-11257.
25. Glenn, G. M., Flyer, D. C., Ellingsworth, L. R., Frech, S. A., Frerichs, D. M., Seid, R. C. & Yu, J. (2007). Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6, 809-819.
26. Goodsell, A., Zhou, F., Gupta, S., Singh, M., Malyala, P., Kazzaz, J., Greer, C., Legg, H., Tang, T. & other authors (2008). β7-Integrin- independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 123, 378-389.
27. Guan, Y., Sajadi, M. M., Kamin-Lewis, R., Fouts, T. R., Dimitrov, A., Zhang, Z., Redfield, R. R., DeVico, A. L., Gallo, R. C. & Lewis, G. K. (2009). Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 106, 3952-3957.
28. Hansen, S. G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D. C., Drummond, D. D., Legasse, A. W., Axthelm, M. K., Oswald, K. & other authors (2009). Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15, 293-299.
29. Hardenberg, G., Planelles, L., Schwarte, C. M., van Bostelen, L., Le Huong, T., Hahne, M. & Medema, J. P. (2007). Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner. Eur J Immunol 37, 2900-2911.
30. 2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26, 812-826.
31. Hinkula, J., Hagbom, M., Wahren, B. & Schroder, U. (2008). Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice. Vaccine 26, 5101-5106.
32. Holmgren, J. & Czerkinsky, C. (2005). Mucosal immunity and vaccines. Nat Med 11, S45-S53.
33. Huang, X., Xu, J., Qiu, C., Ren, L., Liu, L., Wan, Y., Zhang, N., Peng, H. & Shao, Y. (2007). Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 25, 2620-2629. (Pubitemid 46400929)
34. Kamijuku, H., Nagata, Y., Jiang, X., Ichinohe, T., Tashiro, T., Mori, K., Taniguchi, M., Hase, K., Ohno, H. & other authors (2008). Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1, 208-218.
35. Kaminski, R. W. & VanCott, T. C. (1999). Collection and processing of mucosal secretions from mice. Methods Mol Med 17, 329-339.
36. Kantele, A., Kantele, J. M., Savilahti, E., Westerholm, M., Arvilommi, H., Lazarovits, A., Butcher, E. C. & Makela, P. H. (1997). Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 158, 574-579.
37. Kantele, A., Westerholm, M., Kantele, J. M., Makela, P. H. & Savilahti, E. (1999). Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 17, 229-236.
38. Kennedy, J. S., Co, M., Green, S., Longtine, K., Longtine, J., O'Neill, M. A., Adams, J. P., Rothman, A. L., Yu, Q. & other authors (2008). The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26, 4420-4424.
39. Kim, P. H., Eckmann, L., Lee, W. J., Han, W. & Kagnoff, M. F. (1998). Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-β1. J Immunol 160, 1198-1203.
40. Kobayashi, E., Motoki, K., Uchida, T., Fukushima, H. & Koezuka, Y. (1995). KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7, 529-534.
41. Koopman, G., Bogers, W. M., van Gils, M., Koornstra, W., Barnett, S., Morein, B., Lehner, T. & Heeney, J. L. (2007). Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 79, 474-482.
42. Kunisawa, J., Fukuyama, S. & Kiyono, H. (2005). Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr Mol Med 5, 557-572.
43. Lai, L., Vodros, D., Kozlowski, P. A., Montefiori, D. C., Wilson, R. L., Akerstrom, V. L., Chennareddi, L., Yu, T., Kannanganat, S. & other authors (2007). GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369, 153-167.
44. Lehner, T., Wang, Y., Ping, L., Bergmeier, L., Mitchell, E., Cranage, M., Hall, G., Dennis, M., Cook, N. & other authors (1999). The effect of route of immunization on mucosal immunity and protection. J Infect Dis 179, S489-S492.
45. Lobigs, M., Pavy, M., Hall, R. A., Lobigs, P., Cooper, P., Komiya, T., Toriniwa, H. & Petrovsky, N. (2010). An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 91, 1407-1417.
46. + T cell memory. AIDS Res Hum Retroviruses 24, 505-519.
47. Manrique, M., Kozlowski, P. A., Wang, S. W., Wilson, R. L., Micewicz, E., Montefiori, D. C., Mansfield, K. G., Carville, A. & Aldovini, A. (2009). Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol 2, 536-550.
48. Matyas, G. R., Wieczorek, L., Beck, Z., Ochsenbauer-Jambor, C., Kappes, J. C., Michael, N. L., Polonis, V. R. & Alving, C. R. (2009). Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 23, 2069-2077.
49. Mazzoli, S., Lopalco, L., Salvi, A., Trabattoni, D., Lo Caputo, S., Semplici, F., Biasin, M., Bl, C., Cosma, A. & other authors (1999). Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 180, 871-875.
50. Meckelein, B., Externest, D., Schmidt, M. A. & Frey, A. (2003). Contribution of serum immunoglobulin transudate to the antibody immune status of murine intestinal secretions: influence of different sampling procedures. Clin Diagn Lab Immunol 10, 831-834.
51. Ngo-Giang-Huong, N., Candotti, D., Goubar, A., Autran, B., Maynart, M., Sicard, D., Clauvel, J. P., Agut, H., Costagliola, D. & Rouzioux, C. (2001). HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 17, 1435-1446.
52. Ozawa, Y., Suda, T., Nagata, T., Hashimoto, D., Nakamura, Y., Enomoto, N., Inui, N., Koide, Y., Nakamura, H. & Chida, K. (2009). Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen. Am J Respir Cell Mol Biol 41, 440-448.
53. mac-induced immunodeficiency. J Virol 76, 292-302.
54. Pal, R., Taylor, B., Foulke, J. S., Woodward, R., Merges, M., Praschunus, R., Gibson, A. & Reitz, M. (2003). Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J Acquir Immune Defic Syndr 33, 300-307.
55. Pal, R.,Wang, S., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N. & other authors (2005). Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34, 226-236.
56. Pal, R., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I. & other authors (2006). Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348, 341-353.
57. + T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 179, 3035-3046.
58. Petrovsky, N. (2006). Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24, S2-26-S2-29.
59. Petrovsky, N. (2008). Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 7, 7-10.
60. Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., Escobar, M. A., Mooney, J. P., Morris, M. K., Nishiyama, Y., Ghosh, D. & other authors (2010). Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 24, 875-884.
61. Qadri, F., Makela, P. H., Holmgren, J., Albert, M. J., Mannoor, K., Kantele, A., Saha, D., Salam, M. A. & Kantele, J. M. (1998). Enteric infections in an endemic area induce a circulating antibody-secreting cell response with homing potentials to both mucosal and systemic tissues. J Infect Dis 177, 1594-1599.
62. Quiding-Järbrink, M., Nordström, I., Granström, G., Kilander, A., Jertborn, M., Butcher, E. C., Lazarovits, A. I., Holmgren, J. & Czerkinsky, C. (1997). Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest 99, 1281-1286.
63. Raska, M., Moldoveanu, Z., Novak, J., Hel, Z., Novak, L., Bozja, J., Compans, R. W., Yang, C. & Mestecky, J. (2008). Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine 26, 1541-1551.
64. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. & other authors (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361, 2209-2220.
65. Robb, M. L. (2008). Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372, 1857-1858.
66. Sasaki, S., Sumino, K., Hamajima, K., Fukushima, J., Ishii, N., Kawamoto, S., Mohri, H., Kensil, C. R. & Okuda, K. (1998). Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 72, 4931-4939.
67. Scharf, O., Golding, H., King, L. R., Eller, N., Frazier, D., Golding, B. & Scott, D. E. (2001). Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol 75, 6558-6565.
68. Schoenly, K. A. & Weiner, D. B. (2008). Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol 82, 3166-3180.
69. Shang, L., Fukata, M., Thirunarayanan, N., Martin, A. P., Arnaboldi, P., Maussang, D., Berin, C., Unkeless, J. C., Mayer, L. & other authors (2008). Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 135, 529-538.
70. Shattock, R. J., Haynes, B. F., Pulendran, B., Flores, J. & Esparza, J. (2008). Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5, e81.
71. Silva, D. G., Cooper, P. D. & Petrovsky, N. (2004). Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol 82, 611-616.
72. Slifka, M. K. & Ahmed, R. (1996). Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J Immunol Methods 199, 37-46.
73. Srivastava, I., Goodsell, A., Zhou, F., Sun, Y., Burke, B., Barnett, S. & Vajdy, M. (2008). Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine 26, 2796-2806.
74. Staats, H. F., Bradney, C. P., Gwinn, W. M., Jackson, S. S., Sempowski, G. D., Liao, H. X., Letvin, N. L. & Haynes, B. F. (2001). Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol 167, 5386-5394.
75. Stevceva, L. & Ferrari, M. G. (2005). Mucosal adjuvants. Curr Pharm Des 11, 801-811.
76. Tamura, S., Samegai, Y., Kurata, H., Nagamine, T., Aizawa, C. & Kurata, T. (1988). Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6, 409-413.
77. Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R. & Lanzavecchia, A. (2004). An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10, 871-875.
78. Vajdy, M. (2006). Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 7, 267-288.
79. Vajdy, M. & Singh, M. (2005). The role of adjuvants in the development of mucosal vaccines. Expert Opin Biol Ther 5, 953-965.
80. Vajdy, M. & Singh, M. (2006). Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 3, 247-259.
81. van Ginkel, F. W., Jackson, R. J., Yuki, Y. & McGhee, J. R. (2000). Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165, 4778-4782.
82. van Ginkel, F. W., Jackson, R. J., Yoshino, N., Hagiwara, Y., Metzger, D. J., Connell, T. D., Vu, H. L., Martin, M., Fujihashi, K. & McGhee, J. R. (2005). Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73, 6892-6902.
83. Veldt, B. J., van der Vliet, H. J., von Blomberg, B. M., van Vlierberghe, H., Gerken, G., Nishi, N., Hayashi, K., Scheper, R. J., deKnegt, R. J. & other authors (2007). Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 47, 356-365.
84. Wang, S. W., Bertley, F. M., Kozlowski, P. A., Herrmann, L., Manson, K., Mazzara, G., Piatak, M., Johnson, R. P., Carville, A. & other authors (2004). An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 20, 846-859.
85. Wang, S., Pal, R., Mascola, J. R., Chou, T. H., Mboudjeka, I., Shen, S., Liu, Q., Whitney, S., Keen, T. & other authors (2006). Polyvalent HIV- 1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350, 34-47.
86. Wang, S., Kennedy, J. S., West, K., Montefiori, D. C., Coley, S., Lawrence, J., Shen, S., Green, S., Rothman, A. L. & other authors (2008). Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26, 3947-3957.
87. Watanabe, I., Hagiwara, Y., Kadowaki, S. E., Yoshikawa, T., Komase, K., Aizawa, C., Kiyono, H., Takeda, Y., McGhee, J. R. & other authors (2002). Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20, 3443-3455.
88. Watkins, D. I., Burton, D. R., Kallas, E. G., Moore, J. P. & Koff, W. C. (2008). Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14, 617-621.